Review Article
Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
Table 3
Characteristics of patients in the evaluated studies.
| Study | Median age/Male patients % | ECOG > 0 % | Diffuse Histology % | Primary lesion GEJ junction % | Prior Surgery % | Number of metastatic sites >2 % | Peritoneal metastasis % | > II previous lines of treatment % | Previous Ram. % | E | P | E | P | E | P | E | P | E | P | E | P | E | P | E | P | E | P |
| Li et al 2016 | 58/75 | 58/75 | 73 | 83 | NR | NR | 22 | 23 | 69° | 74° | 21 | 22 | 24 | 27 | 34 | 36 | NR | NR | TAGS | 64/75 | 63/69 | 64 | 60 | 16 | 12 | 29 | 28 | 44° | 44° | 54 | 58 | 26 | 31 | 63 | 62 | 34 | 32 | ATTRACTION-2 | 62/69 | 61/73 | 71 | 71 | NR | NR | NR | NR | 60° | 64° | 75°° | 73°° | 19 | 26 | 79 | 72 | 11 | 13 |
|
|
E: experimental arm; P: placebo arm; NR: Not reported; GEJ: Gastroesophageal; Ram: Ramucirumab ° Gastrectomy °° ≥2 organs with metastases
|